Sinotherapeutics (SH:688247) Ge Long Hui A P P·2026-01-29 08:28Core Viewpoint - Xuantai Pharmaceutical (688247.SH) expects a significant decline in net profit for the year 2025, with projections indicating a decrease of 57.65% to 64.71% compared to the previous year [1] Financial Performance - The company anticipates a net profit attributable to shareholders of the parent company ranging from 45.07 million to 54.08 million yuan for 2025 [1] - The expected net profit, excluding non-recurring gains and losses, is projected to be between 29.61 million and 35.53 million yuan, reflecting a year-on-year decline of 68.82% to 74.02% [1] Reasons for Decline - The decline in net profit is primarily attributed to: 1. The ongoing implementation of domestic drug procurement policies, which has led to significant price reductions for some products and a narrowing of profit margins [1] 2. Increased competition in overseas markets and adjustments in tariff policies, resulting in a year-on-year decrease in sales and profitability of related products [1] 3. The company has prudently recognized impairment losses on accounts receivable, inventory, goodwill, etc., in accordance with relevant accounting standards, negatively impacting current net profit [1]